A study collected tumor cells from patients who had acquired the JAK2 mutation and created cell lines that demonstrated that the mutation resulted in complete deletion of the JAK protein and decreased sensitivity of the tumor cells to IFN-γ, which subsequently resulted in the downregulation of MHC-I and PD-L1 expression in the tumor cells [28]. The gene discussed is JAK2; the disease is neoplasm.